AstraZeneca's speedy trial restart splits experts
By MYBRANDBOOK
With the European Medicines Agency (EMA) announcing today that it will also initiate a rolling review of the COVID-19 vaccine developed by Pfizer and BioNTech besides just AstraZeneca’s asset;
Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:
“After interviewing ten experts, there is clearly a split in terms of whether AstraZeneca’s COVID-19 vaccine AZD1222 trials restarted too quickly on the heels of news reports of a trial volunteer having transverse myelitis. With regards to the other vaccine frontrunners, Pfizer and BioNTech’s trial design may have an edge in reporting data earlier - yet Moderna’s may offer data granularity to help decisions as to who should be prioritized for a jab.
“With regards to AstraZeneca’s ongoing trial pause in the US, while some experts agreed with the FDA that more in-depth analysis is needed to conclude these events are truly independent of the vaccine, others noted these cases are unprecedented with the vaccine’s adenovirus vector and so could be due to chance.
“The FDA has broadened its investigations and still has the US trial on hold. Yet, on 1 October, the EMA announced it was starting a rolling review of AZD1222, and after the company confirming on 9 September it had paused its global AZD1222 investigations, all ex-US trials have now restarted, including in Brazil, Japan and South Africa, as well as the UK, where two neurological events occurred in two separate trials.
“However, several experts noted there should be more scrutiny over whether the process has had enough time to properly evaluate if more neurological events could occur later in the trial or in the general population. The first event that triggered an AstraZeneca trial pause was multiple sclerosis, which was concluded as not caused by the vaccine, yet is in the same neurological disease ballpark as transverse myelitis. But other experts noted the vaccine’s cost-benefit ratio would deserve more scrutiny only if there were more of the same events in the trials.
In general, interviewed experts cautioned that any COVID-19 vaccine receiving an Emergency Use Authorization (EUA) from the FDA based on interim analysis data is unlikely to offer detailed information about which subpopulations the authorized vaccine is best suited for.
“Pfizer and BioNTech’s late-phase BNT162b2 trial is designed to report interim data earlier than others in the race and has the potential for a broader label than Moderna’s mRNA-1273 vaccine, which is also based on mRNA technology like BNT162b2. Yet, Pfizer and BioNTech’s early results could leave vaccinators unclear about which patient group would be best suited to use the vaccine.
“Such detail is crucial considering initial vaccine supply is expected to be limited and so would need to be prioritized for distribution. Prioritization discussions is recently in front of mind in the UK, with the head of the UK’s vaccine task force noting that less than half of the UK population is to receive a COVID-19 vaccine.”
BREAKING NEWS
TECHNO TRENDS
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
E-Magazine
TECHNOTAINMENT
Netflix adds 'Moments' feature for saving, sharing scenes from
Netflix has introduced a new “Moments” feature on its mobile app, whic
Jacqueline Fernandez come together with YouTuber Mr. Beast for
Jacqueline Fernandez has partnered with American YouTuber Mr. Beast to b
MOVERS & SHAKERS
Visa elevates Rishi Chhabra as new Country Manager for India
Rishi holds a Master’s in Industrial Engineering from The Ohio State Univ
Genesys welcomes Albert Nel as Senior VP and Regional Sales Le
Genesys continues to deepen its investment in the APAC region. Earlier this
OPEN YOUR EYES
INTERVIEWS
In India, 88% of Indian business leaders are planning to inves
As we move through 2024, it has become increasingly clear that AI is not ju
Bolstering its commitment to help build a truly self-reliant B
CP PLUS is dedicated to spreading a sense of security to every corner of In
HOT PICK
SonicWall Launches TZ80: A Powerful Solution for Remote Office
SonicWall announced today the launch of the TZ80, a groundbreaking securit
Gigabyte X3D Turbo: A Gaming Revolution
GIGABYTE X3D Turbo Mode is a cutting-edge feature that unifies cores distr
MAKE IN INDIA BRANDS
BPE INDIA PVT. LTD.
LUMINOUS POWER TECHNOLOGIES PVT. LTD.
EXIDE INDUSTRIES LTD.
PRAMA HIKVISION INDIA PRIVATE LIMITED
EMINENT CIO'S OF INDIA
ICONS OF INDIA
Icons Of India : NATARAJAN CHANDRASEKARAN
Natarajan Chandrasekaran (Chandra) is the Chairman of Tata Sons, the h...
ICONS OF INDIA : SRIDHAR VEMBU
Sridhar Vembu is the chief executive officer (CEO) of Zoho Corporation...
ICONS OF INDIA : SUNIL BHARTI MITTAL
Sunil Bharti Mittal is the Founder and Chairman of Bharti Enterprises,...
PARTNER SPEAKERS
PSU
IOCL - Indian Oil Corporation Ltd.
IOCL is India’s largest oil refining and marketing company ...
C-DOT - Center of Development of Telematics
India’s premier research and development center focused on telecommu...
NSE - National Stock Exchange
NSE is the leading stock exchange in India....
VIDEOS
Top 25 Brands
Global Indian industry
Indian Tech Talent Excelling The Tech World - REVATHI ADVAITHI, CEO- Flex
Revathi Advaithi, the CEO of Flex, is a dynamic leader driving growth ...
Indian Tech Talent Excelling The Tech World - Aman Bhutani, CEO, GoDaddy
Aman Bhutani, the self-taught techie and CEO of GoDaddy, oversees a co...
Indian Tech Talent Excelling The Tech World - Sanjay Mehrotra, CEO- Micron Technology
Sanjay Mehrotra, the President and CEO of Micron Technology, is at the...
STARNITE AWARDS 2024
ITFORUM 2024
CMO of the Year
WOMEN LEADERSHIP
IMAGE GALLERY
TRENDS IN TECHNOLOGY
MORE VIDEOS
ADVERTISEMENTS
TECHNOLOGY DISRUPTION
UNICORNS REVOLUTIONISING
